Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo, Opdivo Qvantig and Yervoy
nivolumab (IV or with hyaluronidase-nvhy SC) + chemotherapy or IV nivolumab + ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Restricts existing first-line therapy for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma to tumors expressing PD-L1 at least 1. This applies to nivolumab plus fluoropyrimidine and platinum chemotherapy and to IV nivolumab plus ipilimumab.
LAMPGEN ANALYSIS
Why it matters
FDA revised the labeled patient population for the nivolumab-based first-line ESCC regimens after a benefit–risk reassessment.
What research teams should watch
Retain the assay result and distinguish eligible IV regimens from the subcutaneous formulation, which is not labeled for concurrent use with ipilimumab.
PRIMARY RECORDS